loading page

Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis
  • +10
  • Masahiro Irie,
  • Tomohiro Nakano,
  • Saori Katayama,
  • Tasuku Suzuki,
  • Kunihiko Moriya,
  • Yuko Watanabe,
  • Nobu Suzuki,
  • Yuka Saitoh-Nanjyo,
  • Masaei Onuma,
  • Takeshi Rikiishi,
  • Hidetaka Niizuma,
  • Yoji Sasahara,
  • Shigeo Kure
Masahiro Irie
Tohoku University Graduate School of Medicine
Author Profile
Tomohiro Nakano
Tohoku University Graduate School of Medicine
Author Profile
Saori Katayama
Tohoku University Graduate School of Medicine
Author Profile
Tasuku Suzuki
Tohoku University Graduate School of Medicine
Author Profile
Kunihiko Moriya
Tohoku University Graduate School of Medicine
Author Profile
Yuko Watanabe
National Cancer Center Hospital
Author Profile
Nobu Suzuki
Miyagi Children's Hospital
Author Profile
Yuka Saitoh-Nanjyo
Miyagi Children's Hospital
Author Profile
Masaei Onuma
Miyagi Children's Hospital
Author Profile
Takeshi Rikiishi
Miyagi Children's Hospital
Author Profile
Hidetaka Niizuma
Tohoku University Graduate School of Medicine
Author Profile
Yoji Sasahara
Tohoku University Graduate School of Medicine

Corresponding Author:ysasahara@med.tohoku.ac.jp

Author Profile
Shigeo Kure
Tohoku University Graduate School of Medicine
Author Profile

Abstract

Clofarabine (CLO) monotherapy reportedly induces a better clinical response in some patients with refractory Langerhans cell histiocytosis (LCH). We successfully treated two patients with refractory multisystem LCH with CLO monotherapy after recurrence. We administered 23 courses of CLO monotherapy in patient 1 and 4 courses in patient 2. Both patients achieved a durable complete response with acceptable adverse effects of transient myelosuppression. CLO monotherapy is a better therapeutic option for high efficacy and feasibility than other combination chemotherapies or allogeneic hematopoietic stem cell transplantation for refractory LCH.